Salarius Pharma expects Q2 net loss ~$900K, cash $800K; raises $3.8M via equity line

Decoy Therapeutics Inc.

2025-Q2 EPS reported -$1.41

Preliminary Q2 2025 net loss ~$900,000; cash at June 30 was $800,000.
Issued 5.5M shares under equity line for ~$3.8M gross proceeds post-quarter.
As of July 30, 2025, pro forma cash ~$4.5M after issuance.
Unregistered sale to C/M Capital Master Fund LP under purchase agreement.
Preliminary results are subject to adjustment; not yet audited.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.